← Back to Clinical Trials
Recruiting NCT06429956

NCT06429956 Combining Treatment Components in Transdiagnostic Therapy for Anxiety and Depression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06429956
Status Recruiting
Phase
Sponsor University of Aarhus
Condition Depression
Study Type INTERVENTIONAL
Enrollment 93 participants
Start Date 2024-06-28
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
All Conditions
Interventions
Mindful emotion awarenessCognitive flexibility

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 93 participants in total. It began in 2024-06-28 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The present study is a randomized controlled trial that will evaluate the effect of combining two treatment components (i.e., cognitive restructuring and detached mindfulness) drawn from cognitive behavioral therapies (CBTs) that are often combined in clinical practice. However, knowledge about the effect of combining these treatment components is lacking. Therefore, this study aims to explore single, combined, and sequencing effects of these two treatment components in patients with depression and/or anxiety disorders. Furthermore, the study aims to explore possible demographic and clinical moderators of the effects to address the question of what works for whom.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 18 years. 2. A diagnosis of an anxiety disorder (generalized anxiety disorder, social anxiety disorder, or panic disorder with or without agoraphobia) and/or mild to moderate major depressive disorder (MDD) according to DSM-5 (American Psychiatric Association, 2022). 3. Danish language proficiency. 4. Ability and willingness to give informed consent. 5. No or stable antidepressant/antianxiety medication (i.e., same dosage for ≥ 8 weeks). 6. Access to either a smartphone, tablet, or computer with video camera. Exclusion Criteria: 1. Severe depression deemed to require more intense psychotherapy or medication. 2. Persistent depressive disorder (i.e., depressive symptoms have persisted for 2 years or more). 3. Non-stabilized medication (see above). 4. Currently receiving other psychotherapy or counseling. 5. Not capable of participating online. 6. Lack of Danish proficiency. 7. A history of bipolar disorder. 8. Current or past psychosis. 9. Substance abuse or dependence judged to require treatment. 10. Suicide risk requiring immediate hospitalization.

Contact & Investigator

Central Contact

Caroline Nørskov, MSc

✉ cn@psy.au.dk

📞 +4587150193

Principal Investigator

Caroline Nørskov, MSc

PRINCIPAL INVESTIGATOR

University of Aarhus

Frequently Asked Questions

Who can join the NCT06429956 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06429956 currently recruiting?

Yes, NCT06429956 is actively recruiting participants. Contact the research team at cn@psy.au.dk for enrollment information.

Where is the NCT06429956 trial being conducted?

This trial is being conducted at Aarhus, Denmark.

Who is sponsoring the NCT06429956 clinical trial?

NCT06429956 is sponsored by University of Aarhus. The principal investigator is Caroline Nørskov, MSc at University of Aarhus. The trial plans to enroll 93 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology